Literature DB >> 20826490

The use of high doses of oxycodone in an acute palliative care unit.

Sebastiano Mercadante1, Patrizia Ferrera, Fabrizio David, Alessandra Casuccio.   

Abstract

A retrospective study of patients who were prescribed controlled-release oxycodone (CRO) in a period of 3 years (2006-2008) was performed. A total of 212 patients were prescribed at discharge CRO for background analgesia; 129, 43, and 40 patients were prescribed doses of oxycodone of less than 120 mg/day (group L), 120 to 240 mg/day (group M), and more than 240 mg/day (group L), respectively. No differences in gender, primary diagnosis, and pain mechanisms were found, but doses were significantly lower in older patients (P < .0005). At discharge, adverse effects were mild and only a minority of patients were switched to other opioids. This study demonstrated that CRO administered in larger doses was safe and effective, showing versatility and flexibility similar to morphine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826490     DOI: 10.1177/1049909110381378

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  7 in total

1.  Clarifications on oxycodone-naloxone combination in cancer pain management.

Authors:  Sebastiano Mercadante
Journal:  Support Care Cancer       Date:  2012-04-14       Impact factor: 3.603

2.  High doses of oxycodone-naloxone combination may provide poor analgesia.

Authors:  Sebastiano Mercadante; Patrizia Ferrera; Claudio Adile
Journal:  Support Care Cancer       Date:  2011-06-09       Impact factor: 3.603

3.  Switching from oxycodone to methadone in advanced cancer patients.

Authors:  Sebastiano Mercadante; Patrizia Ferrera; Patrizia Villari; Claudio Adile; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2011-09-07       Impact factor: 3.603

4.  Comparison of oxycodone and sufentanil for patient-controlled intravenous analgesia after laparoscopic radical gastrectomy: A randomized double-blind clinical trial.

Authors:  Na Wang; Honglan Zhou; Xuesong Song; Jinguo Wang
Journal:  Anesth Essays Res       Date:  2016 Sep-Dec

5.  Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial.

Authors:  Xiaobing Xiang; Xiaohong Yuan; Yanhong Lian; Jun Fang; Yingli Wu
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

6.  Use of high-dose oxycodone hydrochloride in patients with visceral and neuropathic pain.

Authors:  Jakub Kucharz; Iwona Filipczak-Bryniarska; Anna Michalowska-Kaczmarczyk; Roman M Herman; Krzysztof Krzemieniecki
Journal:  Contemp Oncol (Pozn)       Date:  2015-07-08

7.  A systematic review of the risk factors for clinical response to opioids for all-age patients with cancer-related pain and presentation of the paediatric STOP pain study.

Authors:  Ersilia Lucenteforte; Laura Vagnoli; Alessandra Pugi; Giada Crescioli; Niccolò Lombardi; Roberto Bonaiuti; Maurizio Aricò; Sabrina Giglio; Andrea Messeri; Alessandro Mugelli; Alfredo Vannacci; Valentina Maggini
Journal:  BMC Cancer       Date:  2018-05-18       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.